FTE UTILIZATION
70.0%
2.8 / 4 FTE
ACTIVE TRIALS
2
of 3 max
ENROLLMENT RATE
2.7
patients/month
PERFORMANCE SCORE
65
out of 100
MONTHLY OP COST
$35K
18% overhead
ACTIVE TRIALS AT THIS SITE
| PROTOCOL | STATUS | ENROLLMENT | SCREEN FAILURES | FTE |
|---|---|---|---|---|
METABOFIX-1 Type 2 Diabetes Mellitus | 60 / 90 67% | 9 | 2.0 |
RECRUITMENT POOLS BY THERAPEUTIC AREA
Endocrinology
760 of 900 available
15.6%
+12/mo
Oncology
1,000 of 1,200 available
16.7%
+16/mo
PERFORMANCE BY THERAPEUTIC AREA
| THERAPEUTIC AREA | TRIALS | AVG ENROLLMENT | SCREEN FAILURE | DROPOUT |
|---|---|---|---|---|
| Endocrinology | 3 | 2.5/mo | 24.0% | 9.0% |
| Oncology | 2 | 3.0/mo | 27.0% | 11.0% |
SITE INFORMATION
PRINCIPAL INVESTIGATOR
Dr. Michael Park, MD
ADDRESS
975 East Third Street
Chattanooga, TN 37403
Chattanooga, TN 37403
CONTACT
michael.park@medpoint.com
(423) 555-0234
CERTIFICATIONS
CITIGCP
SPECIALTIES
EndocrinologyOncology
CAPACITY BY THERAPEUTIC AREA
Endocrinology
1 / 2
Oncology
1 / 2
HISTORICAL PERFORMANCE
Trials Completed5
On-Time Rate80%
Budget Accuracy±7.2%
Avg Screen Failure25.0%
Avg Dropout10.0%